0000827187 12/28 2024 Q3 FALSE P5Y P3Y 516 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure snbr:litigationDemand 0000827187 2023-12-31 2024-09-28 0000827187 2024-09-28 0000827187 2023-12-30 0000827187 2024-06-30 2024-09-28 0000827187 2023-07-02 2023-09-30 0000827187 2023-01-01 2023-09-30 0000827187 us-gaap:CommonStockMember 2023-12-30 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-12-30 0000827187 us-gaap:RetainedEarningsMember 2023-12-30 0000827187 us-gaap:RetainedEarningsMember 2023-12-31 2024-03-30 0000827187 2023-12-31 2024-03-30 0000827187 us-gaap:CommonStockMember 2023-12-31 2024-03-30 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 2024-03-30 0000827187 us-gaap:CommonStockMember 2024-03-30 0000827187 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0000827187 us-gaap:RetainedEarningsMember 2024-03-30 0000827187 2024-03-30 0000827187 us-gaap:RetainedEarningsMember 2024-03-31 2024-06-29 0000827187 2024-03-31 2024-06-29 0000827187 us-gaap:CommonStockMember 2024-03-31 2024-06-29 0000827187 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 2024-06-29 0000827187 us-gaap:CommonStockMember 2024-06-29 0000827187 us-gaap:AdditionalPaidInCapitalMember 2024-06-29 0000827187 us-gaap:RetainedEarningsMember 2024-06-29 0000827187 2024-06-29 0000827187 us-gaap:RetainedEarningsMember 2024-06-30 2024-09-28 0000827187 us-gaap:CommonStockMember 2024-06-30 2024-09-28 0000827187 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 2024-09-28 0000827187 us-gaap:CommonStockMember 2024-09-28 0000827187 us-gaap:AdditionalPaidInCapitalMember 2024-09-28 0000827187 us-gaap:RetainedEarningsMember 2024-09-28 0000827187 us-gaap:CommonStockMember 2022-12-31 0000827187 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000827187 us-gaap:RetainedEarningsMember 2022-12-31 0000827187 2022-12-31 0000827187 us-gaap:RetainedEarningsMember 2023-01-01 2023-04-01 0000827187 2023-01-01 2023-04-01 0000827187 us-gaap:CommonStockMember 2023-01-01 2023-04-01 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-04-01 0000827187 us-gaap:CommonStockMember 2023-04-01 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 0000827187 us-gaap:RetainedEarningsMember 2023-04-01 0000827187 2023-04-01 0000827187 us-gaap:RetainedEarningsMember 2023-04-02 2023-07-01 0000827187 2023-04-02 2023-07-01 0000827187 us-gaap:CommonStockMember 2023-04-02 2023-07-01 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-04-02 2023-07-01 0000827187 us-gaap:CommonStockMember 2023-07-01 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 0000827187 us-gaap:RetainedEarningsMember 2023-07-01 0000827187 2023-07-01 0000827187 us-gaap:RetainedEarningsMember 2023-07-02 2023-09-30 0000827187 us-gaap:CommonStockMember 2023-07-02 2023-09-30 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-07-02 2023-09-30 0000827187 us-gaap:CommonStockMember 2023-09-30 0000827187 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000827187 us-gaap:RetainedEarningsMember 2023-09-30 0000827187 2023-09-30 0000827187 us-gaap:FairValueInputsLevel1Member us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-28 0000827187 us-gaap:FairValueInputsLevel1Member us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000827187 us-gaap:FairValueInputsLevel1Member us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-28 0000827187 us-gaap:FairValueInputsLevel1Member us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-30 0000827187 us-gaap:TradeNamesMember 2023-12-30 0000827187 us-gaap:TradeNamesMember 2024-09-28 0000827187 us-gaap:PatentsMember 2023-12-30 0000827187 us-gaap:PatentsMember 2024-09-28 0000827187 us-gaap:PatentsMember 2024-06-30 2024-09-28 0000827187 us-gaap:PatentsMember 2023-07-02 2023-09-30 0000827187 us-gaap:PatentsMember 2023-12-31 2024-09-28 0000827187 us-gaap:PatentsMember 2023-01-01 2023-09-30 0000827187 us-gaap:LineOfCreditMember 2024-09-28 0000827187 snbr:DebtCovenantPeriodOneMember us-gaap:LineOfCreditMember 2024-09-28 0000827187 snbr:DebtCovenantPeriodTwoMember us-gaap:LineOfCreditMember 2024-09-28 0000827187 snbr:DebtCovenantPeriodThreeMember us-gaap:LineOfCreditMember 2024-09-28 0000827187 us-gaap:LineOfCreditMember snbr:DebtCovenantPeriodTwoMember srt:ScenarioForecastMember 2024-12-28 0000827187 snbr:DebtCovenantPeriodThreeAndThereafterMember us-gaap:LineOfCreditMember 2024-09-28 0000827187 srt:MinimumMember snbr:RetailStoreLeasesMember 2024-09-28 0000827187 srt:MaximumMember snbr:RetailStoreLeasesMember 2024-09-28 0000827187 srt:MaximumMember snbr:OfficeAndManufacturingLeasesMember 2024-09-28 0000827187 srt:MinimumMember snbr:LeaseVehiclesAndCertainEquipmentUnderOperatingLeasesMember 2024-09-28 0000827187 srt:MaximumMember snbr:LeaseVehiclesAndCertainEquipmentUnderOperatingLeasesMember 2024-09-28 0000827187 us-gaap:OtherCurrentAssetsMember 2024-09-28 0000827187 us-gaap:OtherCurrentAssetsMember 2023-12-30 0000827187 us-gaap:OtherNoncurrentAssetsMember 2024-09-28 0000827187 us-gaap:OtherNoncurrentAssetsMember 2023-12-30 0000827187 us-gaap:OtherCurrentLiabilitiesMember 2024-09-28 0000827187 us-gaap:OtherCurrentLiabilitiesMember 2023-12-30 0000827187 us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-28 0000827187 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-30 0000827187 snbr:SleepIQTechnologyMember srt:MinimumMember 2023-12-31 2024-09-28 0000827187 snbr:SleepIQTechnologyMember srt:MaximumMember 2023-12-31 2024-09-28 0000827187 snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2023-07-02 2023-09-30 0000827187 snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-09-30 0000827187 snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2023-12-31 2024-09-28 0000827187 snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2024-06-30 2024-09-28 0000827187 snbr:RetailChannelMember 2024-06-30 2024-09-28 0000827187 snbr:RetailChannelMember 2023-07-02 2023-09-30 0000827187 snbr:RetailChannelMember 2023-12-31 2024-09-28 0000827187 snbr:RetailChannelMember 2023-01-01 2023-09-30 0000827187 snbr:OnlinePhoneChatAndOtherMember 2024-06-30 2024-09-28 0000827187 snbr:OnlinePhoneChatAndOtherMember 2023-07-02 2023-09-30 0000827187 snbr:OnlinePhoneChatAndOtherMember 2023-12-31 2024-09-28 0000827187 snbr:OnlinePhoneChatAndOtherMember 2023-01-01 2023-09-30 0000827187 snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember 2024-06-30 2024-09-28 0000827187 snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember 2023-07-02 2023-09-30 0000827187 snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember 2023-12-31 2024-09-28 0000827187 snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember 2023-01-01 2023-09-30 0000827187 us-gaap:EmployeeStockOptionMember 2024-06-30 2024-09-28 0000827187 us-gaap:EmployeeStockOptionMember 2023-07-02 2023-09-30 0000827187 us-gaap:EmployeeStockOptionMember 2023-12-31 2024-09-28 0000827187 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000827187 2023-10-01 2023-12-30 0000827187 srt:MinimumMember 2024-09-28 0000827187 srt:MaximumMember 2024-09-28 0000827187 us-gaap:ContractTerminationMember 2024-06-30 2024-09-28 0000827187 us-gaap:ContractTerminationMember 2023-12-31 2024-09-28 0000827187 us-gaap:EmployeeSeveranceMember 2024-06-30 2024-09-28 0000827187 us-gaap:EmployeeSeveranceMember 2023-12-31 2024-09-28 0000827187 snbr:ProfessionalFeesMember 2024-06-30 2024-09-28 0000827187 snbr:ProfessionalFeesMember 2023-12-31 2024-09-28 0000827187 2023-10-01 2024-09-28 0000827187 us-gaap:ContractTerminationMember 2023-10-01 2024-09-28 0000827187 us-gaap:EmployeeSeveranceMember 2023-10-01 2024-09-28 0000827187 snbr:ProfessionalFeesMember 2023-10-01 2024-09-28 0000827187 us-gaap:PendingLitigationMember 2022-10-05 2022-10-12 0000827187 snbr:DeborahL.KilpatrickMember 2023-12-31 2024-09-28 0000827187 snbr:DeborahL.KilpatrickMember 2024-06-30 2024-09-28 0000827187 snbr:DeborahL.KilpatrickMember 2024-09-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 28, 2024
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-25121
_______________________________________________________________________
SLEEP NUMBER CORPORATION
(Exact name of registrant as specified in its charter)

Minnesota |  | 41-1597886
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

1001 Third Avenue South |  |
Minneapolis, |  | Minnesota |  | 55404
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (763) 551-7000
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.01 per share |  | SNBR |  | Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☐ |  | Accelerated filer | ☒
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
|  |  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of September 28, 2024, 22,371,000 shares of the registrant’s Common Stock were outstanding.

i | 3Q 2023 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
INDEX

| Page
PART I: FINANCIAL INFORMATION | 1
Item 1. | Financial Statements (unaudited) | 1
| Condensed Consolidated Balance Sheets | 1
| Condensed Consolidated Statements of Operations | 2
| Condensed Consolidated Statements of Shareholders' Deficit | 3
| Condensed Consolidated Statements of Cash Flows | 4
| Notes to Condensed Consolidated Financial Statements | 5
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 15
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 26
Item 4. | Controls and Procedures | 26
PART II: OTHER INFORMATION | 27
Item 1. | Legal Proceedings | 27
Item 1A. | Risk Factors | 27
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 28
Item 3. | Defaults Upon Senior Securities | 28
Item 4. | Mine Safety Disclosures | 28
Item 5. | Other Information | 28
Item 6. | Exhibits | 29
SIGNATURES | 30

1 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of contents
PART I: FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(unaudited - in thousands, except per share amounts)

| September 28, 2024 |  | December 30, 2023
Assets |  |  |
Current assets: |  |  |
Cash and cash equivalents | $1,592 |  | $2,539
Accounts receivable, net of allowances of $1,134 and $1,437, respectively | 17,026 |  | 26,859
Inventories | 93,039 |  | 115,433
Prepaid expenses | 17,827 |  | 16,660
Other current assets | 40,784 |  | 44,637
Total current assets | 170,268 |  | 206,128
Non-current assets: |  |  |
Property and equipment, net | 140,406 |  | 179,503
Operating lease right-of-use assets | 367,133 |  | 395,411
Goodwill and intangible assets, net | 66,468 |  | 66,634
Deferred income taxes | 27,267 |  | 20,253
Other non-current assets | 93,109 |  | 82,951
Total assets | $864,651 |  | $950,880
Liabilities and Shareholders’ Deficit |  |  |
Current liabilities: |  |  |
Borrowings under revolving credit facility | $516,500 |  | $539,500
Accounts payable | 127,990 |  | 135,901
Customer prepayments | 43,514 |  | 49,143
Accrued sales returns | 19,688 |  | 22,402
Compensation and benefits | 28,909 |  | 28,273
Taxes and withholding | 17,685 |  | 17,134
Operating lease liabilities | 82,488 |  | 81,760
Other current liabilities | 57,268 |  | 61,958
Total current liabilities | 894,042 |  | 936,071
Non-current liabilities: |  |  |
Operating lease liabilities | 318,665 |  | 351,394
Other non-current liabilities | 100,728 |  | 105,343
Total liabilities | 1,313,435 |  | 1,392,808
Shareholders’ deficit: |  |  |
Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding | — |  | —
Common stock, $0.01 par value; 142,500 shares authorized, 22,371 and 22,235 shares issued and outstanding, respectively | 224 |  | 222
Additional paid-in capital | 25,527 |  | 16,716
Accumulated deficit | (474,535) |  | (458,866)
Total shareholders’ deficit | (448,784) |  | (441,928)
Total liabilities and shareholders’ deficit | $864,651 |  | $950,880

See accompanying notes to condensed consolidated financial statements.

2 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(unaudited - in thousands, except per share amounts)

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Net sales | $426,617 |  | $472,648 |  | $1,305,479 |  | $1,457,964
Cost of sales | 167,089 |  | 201,537 |  | 528,287 |  | 612,343
Gross profit | 259,528 |  | 271,111 |  | 777,192 |  | 845,621
Operating expenses: |  |  |  |  |  |  |
Sales and marketing | 205,480 |  | 221,143 |  | 596,392 |  | 649,410
General and administrative | 33,070 |  | 31,948 |  | 111,722 |  | 111,144
Research and development | 10,583 |  | 12,633 |  | 34,602 |  | 42,521
Restructuring costs | 1,963 |  | — |  | 14,382 |  | —
Total operating expenses | 251,096 |  | 265,724 |  | 757,098 |  | 803,075
Operating income | 8,432 |  | 5,387 |  | 20,094 |  | 42,546
Interest expense, net | 12,057 |  | 10,958 |  | 36,626 |  | 30,008
(Loss) income before income taxes | (3,625) |  | (5,571) |  | (16,532) |  | 12,538
Income tax (benefit) expense | (489) |  | (3,253) |  | (863) |  | 2,637
Net (loss) income | $(3,136) |  | $(2,318) |  | $(15,669) |  | $9,901
Basic net (loss) income per share: |  |  |  |  |  |  |
Net (loss) income per share – basic | $(0.14) |  | $(0.10) |  | $(0.69) |  | $0.44
Weighted-average shares – basic | 22,643 |  | 22,479 |  | 22,588 |  | 22,412
Diluted net (loss) income per share: |  |  |  |  |  |  |
Net (loss) income per share – diluted | $(0.14) |  | $(0.10) |  | $(0.69) |  | $0.44
Weighted-average shares – diluted | 22,643 |  | 22,479 |  | 22,588 |  | 22,558

See accompanying notes to condensed consolidated financial statements.

3 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Condensed Consolidated Statements of Shareholders’ Deficit
(unaudited - in thousands)

| Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Total
| Shares |  | Amount |  |  |
Balance at December 30, 2023 | 22,235 |  | $222 |  | $16,716 |  | $(458,866) |  | $(441,928)
Net loss | — |  | — |  | — |  | (7,482) |  | (7,482)
Stock-based compensation | 134 |  | 1 |  | 4,116 |  | — |  | 4,117
Repurchases of common stock | (43) |  | — |  | (570) |  | — |  | (570)
Balance at March 30, 2024 | 22,326 |  | $223 |  | $20,262 |  | $(466,348) |  | $(445,863)
Net loss | — |  | — |  | — |  | (5,051) |  | (5,051)
Stock-based compensation | 32 |  | 1 |  | 3,991 |  | — |  | 3,992
Repurchases of common stock | (3) |  | — |  | (42) |  | — |  | (42)
Balance at June 29, 2024 | 22,355 |  | $224 |  | $24,211 |  | $(471,399) |  | $(446,964)
Net loss | — |  | — |  | — |  | (3,136) |  | (3,136)
Stock-based compensation | 24 |  | — |  | 1,432 |  | — |  | 1,432
Repurchases of common stock | (8) |  | — |  | (116) |  | — |  | (116)
Balance at September 28, 2024 | 22,371 |  | $224 |  | $25,527 |  | $(474,535) |  | $(448,784)

| Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Total
| Shares |  | Amount |  |  |
Balance at December 31, 2022 | 22,014 |  | $220 |  | $5,182 |  | $(443,579) |  | $(438,177)
Net income | — |  | — |  | — |  | 11,465 |  | 11,465
Exercise of common stock options | 17 |  | — |  | 389 |  | — |  | 389
Stock-based compensation | 271 |  | 3 |  | 4,636 |  | — |  | 4,639
Repurchases of common stock | (118) |  | (1) |  | (3,362) |  | — |  | (3,363)
Balance at April 1, 2023 | 22,184 |  | $222 |  | $6,845 |  | $(432,114) |  | $(425,047)
Net income | — |  | — |  | — |  | 754 |  | 754
Exercise of common stock options | 3 |  | — |  | 39 |  | — |  | 39
Stock-based compensation | 33 |  | — |  | 5,251 |  | — |  | 5,251
Repurchases of common stock | (6) |  | — |  | (138) |  | — |  | (138)
Balance at July 1, 2023 | 22,214 |  | $222 |  | $11,997 |  | $(431,360) |  | $(419,141)
Net loss | — |  | — |  | — |  | (2,318) |  | (2,318)
Stock-based compensation | 22 |  | — |  | 982 |  | — |  | 982
Repurchases of common stock | (8) |  | — |  | (210) |  | — |  | (210)
Balance at September 30, 2023 | 22,228 |  | $222 |  | $12,769 |  | $(433,678) |  | $(420,687)

See accompanying notes to condensed consolidated financial statements.

4 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(unaudited - in thousands)

| Nine Months Ended
| September 28, 2024 |  | September 30, 2023
Cash flows from operating activities: |  |  |
Net (loss) income | $(15,669) |  | $9,901
Adjustments to reconcile net (loss) income to net cash provided by operating activities: |  |  |
Depreciation and amortization | 50,379 |  | 55,196
Stock-based compensation | 9,541 |  | 10,872
Net loss on disposals and impairments of assets | 2,457 |  | 464
Deferred income taxes | (7,014) |  | (13,433)
Changes in operating assets and liabilities: |  |  |
Accounts receivable | 9,833 |  | 7,374
Inventories | 22,394 |  | (2,190)
Income taxes | 1,708 |  | 3,571
Prepaid expenses and other assets | (8,012) |  | (5,903)
Accounts payable | 4,980 |  | 5,199
Customer prepayments | (5,629) |  | (27,279)
Accrued compensation and benefits | 788 |  | (6,923)
Other taxes and withholding | (1,157) |  | 5
Other accruals and liabilities | (13,775) |  | (5,038)
Net cash provided by operating activities | 50,824 |  | 31,816
Cash flows from investing activities: |  |  |
Purchases of property and equipment | (17,218) |  | (48,022)
Issuance of note receivable | (2,942) |  | (1,317)
Proceeds from sales of property and equipment | 156 |  | 10
Net cash used in investing activities | (20,004) |  | (49,329)
Cash flows from financing activities: |  |  |
Net (decrease) increase in short-term borrowings | (31,039) |  | 20,334
Repurchases of common stock | (728) |  | (3,711)
Proceeds from issuance of common stock | — |  | 428
Debt issuance costs | — |  | (424)
Net cash (used in) provided by financing activities | (31,767) |  | 16,627
Net decrease in cash and cash equivalents | (947) |  | (886)
Cash and cash equivalents, at beginning of period | 2,539 |  | 1,792
Cash and cash equivalents, at end of period | $1,592 |  | $906

See accompanying notes to condensed consolidated financial statements.

5 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
1. Business and Summary of Significant Accounting Policies
Business & Basis of Presentation
The Company prepared the condensed consolidated financial statements as of and for the three and nine months ended
September 28, 2024 of Sleep Number Corporation and its 100%-owned subsidiaries (Sleep Number or the Company),
without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) and they reflect, in
the opinion of management, all normal recurring adjustments, including the elimination of all significant intra-entity
balances and transactions, necessary to present fairly its financial position as of September 28, 2024 and December 30,
2023, and the consolidated results of operations and cash flows for the periods presented. The historical and quarterly
consolidated results of operations may not be indicative of the results that may be achieved for the full year or any future
period.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S.
generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and
regulations. These condensed consolidated financial statements should be read in conjunction with the most recent
audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for
the fiscal year ended December 30, 2023 and other recent filings with the SEC.
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to
make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the
reported amounts of sales, expenses and income taxes during the reporting period. Predicting future events is inherently
an imprecise activity and, as such, requires the use of judgment. As future events and their effects cannot be determined
with precision, actual results could differ significantly from these estimates. Changes in these estimates will be reflected
in the consolidated financial statements in future periods and could be material. The Company’s critical accounting
policies consist of stock-based compensation, warranty liabilities and revenue recognition.
Income Taxes
Income tax benefit totaled $0.9 million for the nine months ended September 28, 2024, compared with income tax
expense of $3 million last year. The change in income tax expense was primarily due to the change in (loss) income
before income taxes levels and the impact of discrete tax expenses. Discrete tax expense, primarily stock-based
compensation tax shortfalls, was $2.6 million for the nine months ended September 28, 2024, compared to $1.1 million
for the same period last year.
Recent Issued Accounting Pronouncements Not Yet Adopted
Segment Reporting (Topic 280)
In November 2023, the Financial Accounting Standards Board issued guidance within Accounting Standards Update
(ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU requires
that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this
ASU and all existing disclosures in Topic 280. The Company has determined that its current business and operations
consist of a single business segment and a single reporting unit.
The amendments in this ASU are intended to improve segment disclosure requirements, primarily through enhanced
disclosures about significant segment expenses. The key amendments included in this ASU:
•Require disclosure on an annual and interim basis, of significant segment expenses that are regularly provided to
the chief operating decision maker (CODM) and are included within each reported measure of segment profit
and loss.
•Require disclosure on an annual and interim basis, an amount for other segment items (defined in this ASU) and
a description of its composition.

6 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
•Clarify that if the CODM uses more than one measure of the segment’s profit or loss in assessing performance,
one or more of those additional measures may be reported.
•Require disclosure of the title and position of the CODM and an explanation of how the CODM uses the
reported measure(s) of segment profit or loss in assessing performance.
This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning
after December 15, 2024, with early adoption permitted. This guidance is required to be adopted by the Company
beginning with the annual period of 2024. The amendments should be applied retrospectively to all prior periods
presented in the consolidated financial statements. The Company is currently evaluating the impact of this ASU on the
Company’s consolidated financial statements.
Currently, management does not believe that any other recently issued, but not yet effective accounting
pronouncements, if currently adopted, would have a material impact on the Company’s unaudited condensed
consolidated financial statements.
2. Fair Value Measurements
At September 28, 2024 and December 30, 2023, the Company had $20 million and $19 million, respectively, of debt
and equity securities that fund the deferred compensation plan and are classified in other non-current assets. The
Company also had corresponding deferred compensation plan liabilities of $20 million and $19 million at September 28,
2024 and December 30, 2023, respectively, which are included in other non-current liabilities. The majority of the debt
and equity securities are Level 1 as they trade with sufficient frequency and volume to enable the Company to obtain
pricing information on an ongoing basis. Unrealized gains/(losses) on the debt and equity securities offset those
associated with the corresponding deferred compensation plan liabilities.
3. Inventories
Inventories consisted of the following (in thousands):

| September 28, 2024 |  | December 30, 2023
Raw materials | $6,638 |  | $9,092
Work in progress | 133 |  | 92
Finished goods | 86,268 |  | 106,249
| $93,039 |  | $115,433

4. Goodwill and Intangible Assets, Net
Goodwill and Indefinite-lived Intangible Assets
Goodwill was $64 million at September 28, 2024 and December 30, 2023. Indefinite-lived trade name/trademarks
totaled $1.4 million at both September 28, 2024 and December 30, 2023.
Definite-lived Intangible Assets
Patents were $2.0 million at both September 28, 2024 and December 30, 2023. Accumulated amortization was $0.9
million at September 28, 2024 and $0.8 million at December 30, 2023. Amortization expense for both the three months
ended September 28, 2024 and September 30, 2023, was $55 thousand, and for both the nine months ended
September 28, 2024 and September 30, 2023 was $0.2 million.

7 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
Annual amortization for patents for subsequent years are as follows (in thousands):

2024 (excluding the nine months ended September 28, 2024 ) |  | $55
2025 |  | 226
2026 |  | 222
2027 |  | 222
2028 |  | 155
2029 |  | 99
Thereafter |  | 46
Total future amortization for definite-lived intangible assets |  | $1,025

5. Credit Agreement
As of September 28, 2024, the Company’s credit facility had a total commitment amount of $680 million. The credit
facility is for general corporate purposes and to meet sea sonal working capital requirements. The Amended and
Restated Credit and Security Agreement, dated February 14, 2018, among the Company, U.S. Bank National Association
and the several banks and other financial institutions from time to time party thereto (as amended, the Credit
Agreement), includes an accordion feature which allows the Company to increase the amount of the credit facility from
$680 million to $1.0 billion, subject to lenders’ approval. The Credit Agreement provides the lenders with a collateral
security interest in substantially all of the Company’s assets and those of its subsidiaries and requires the Company to
comply with, among other things, a maximum net leverage ratio and a minimum interest coverage ratio.
The maximum net leverage ratio permitted by the Credit Agreement is 5.00 to 1.00 for the quarterly period ended
September 28, 2024; 4.80 to 1.00 for the quarterly reporting period ending December 28, 2024; and 4.00 to 1.00 for
each quarterly reporting period occurring thereafter until maturity.
The minimum interest coverage ratio permitted by the Credit Agreement is 1.50 to 1.00 for both quarterly reporting
periods ending September 28, 2024 and December 28, 2024; and 3.00 to 1.00 for each quarterly reporting period
occurring thereafter until maturity.
The carrying amount of the outstanding borrowings under the Credit Agreement approximates fair value because
interest rates approximate the current rates available to the Company. Under the terms of the Credit Agreement, the
Company pays a variable rate of interest and a commitment fee based on its leverage ratio. The Credit Agreement
matures in December 2026. The Company was in compliance with all financial covenants as of September 28, 2024.
The following table summarizes the Company’s borrowings under the credit facility ($ in thousands):

| September 28, 2024 |  | December 30, 2023
Outstanding borrowings | $516,500 |  | $539,500
Outstanding letters of credit | $7,147 |  | $7,147
Additional borrowing capacity | $156,353 |  | $138,353
Weighted-average interest rate | 8.2% |  | 8.5%

6. Leases
The Company leases its retail, office and manufacturing space under operating leases which, in addition to the minimum
lease payments, may require payment of a proportionate share of the real estate taxes and certain building operating
expenses. While the Company’s local market development approach generally results in long-term participation in given
markets, the retail store leases generally provide for an initial lease term of five to ten years. The Company’s office and
manufacturing leases provide for an initial lease term of up to fifteen years. In addition, the Company’s mall-based retail
store leases may require payment of variable rent based on net sales in excess of certain thresholds. Certain leases may

8 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
contain options to extend the term of the original lease. The exercise of lease renewal options is at the Company’s sole
discretion. Lease options are included in the lease term only if exercise is reasonably certain at lease commencement.
The Company’s lease agreements do not contain any material residual value guarantees. The Company also leases
vehicles and certain equipment under operating leases with an initial lease term of three to six years.
The Company’s operating lease costs include facility, vehicle and equipment lease costs, but exclude variable lease
costs. Operating lease costs are recognized on a straight-line basis over the lease term, after consideration of rent
escalations and rent holidays. The lease term for purposes of the calculation begins on the earlier of the lease
commencement date or the date the Company takes possession of the property. During lease renewal negotiations that
extend beyond the original lease term, the Company estimates straight-line rent expense based on current market
conditions. Variable lease costs are recorded when it is probable the cost has been incurred and the amount can be
reasonably estimated.
At September 28, 2024, the Company’s finance right-of-use assets and lease liabilities were not significant.
Lease costs were as follows (in thousands):

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Operating lease costs(1) | $26,445 |  | $28,517 |  | $80,180 |  | $84,889
Variable lease costs(2) | $42 |  | $48 |  | $1 |  | $230

___________________________
(1)Includes short-term lease costs which are not significant.
(2)Variable lease costs include adjustments to percentage rent.
The maturities of operating lease liabilities as of September 28, 2024, were as follows(1) (in thousands):

2024 (excluding the nine months ended September 28, 2024) | $26,997
2025 | 103,848
2026 | 91,716
2027 | 75,205
2028 | 63,060
2029 | 43,265
Thereafter | 73,361
Total operating lease payments(2) | 477,452
Less: Interest | 76,299
Present value of operating lease liabilities | $401,153

___________________________
(1)F uture payments for real estate taxes and certain building operating expenses for which the Company is obligated are not included in the operating
lease liabilities. T otal operating lease payments exclude $17 million of legally binding minimum lease payments for leases signed but not yet
commenced.
(2)Includes the current portion of $82 million for operating lease liabilities.
Other information related to operating leases was as follows:

|  | September 28, 2024 |  | December 30, 2023
Weighted-average remaining lease term (in years) |  | 5.5 |  | 5.9
Weighted-average discount rate |  | 6.6% |  | 6.5%

9 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)

|  | Nine Months Ended
(in thousands) |  | September 28, 2024 |  | September 30, 2023
Cash paid for amounts included in present value of operating lease liabilities |  | $81,089 |  | $80,650
Right-of-use assets obtained in exchange for operating lease liabilities |  | $29,390 |  | $54,172

7. Repurchases of Common Stock
For the three months ended September 28, 2024 and September 30, 2023, we repurchased $0.1 million and $0.2
million, respectively, of common stock in connection with the vesting of restricted stock grants. For the nine months
ended September 28, 2024 and September 30, 2023, we repurchased $0.7 million and $3.7 million, respectively, of
common stock in connection with the vesting of restricted stock grants. We made no purchases under the Board-
approved stock purchase plan in either period. As of September 28, 2024, the remaining authorization under the Board-
approved $600 million share repurchase program was $348 million.
8. Revenue Recognition
Deferred contract assets and deferred contract liabilities are included in the condensed consolidated balance sheets as
follows (in thousands):

| September 28, 2024 |  | December 30, 2023
Deferred contract assets included in: |  |  |
Other current assets | $30,329 |  | $28,567
Other non-current assets | 50,981 |  | 54,795
| $81,310 |  | $83,362

| September 28, 2024 |  | December 30, 2023
Deferred contract liabilities included in: |  |  |
Other current liabilities | $38,395 |  | $36,421
Other non-current liabilities | 63,594 |  | 69,098
| $101,989 |  | $105,519

Deferred revenue and costs related to SleepIQ® technology are currently recognized on a straight-line basis over the
product's estimated life of 4.5 to 5.0 years because the Company’s inputs are generally expended evenly throughout the
performance period. During both the three months ended September 28, 2024 and September 30, 2023, the Company
recognized revenue of $10 million, that was included in the deferred contract liability balances at the beginning of the
respective periods. During both the nine months ended September 28, 2024 and September 30, 2023, the Company
recognized revenue of $28 million, that was included in the deferred contract liability balances at the beginning of the
respective periods.
Revenue from goods and services transferred to customers at a point in time accounted for a pproximate ly 98% of
revenues for both the three and nine months ended September 28, 2024 and September 30, 2023.

10 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
Net sales were as follows (in thousands):

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Retail stores | $374,593 |  | $409,268 |  | $1,147,931 |  | $1,270,076
Online, phone, chat and other | 52,024 |  | 63,380 |  | 157,548 |  | 187,888
Total Company | $426,617 |  | $472,648 |  | $1,305,479 |  | $1,457,964

Obligation for Sales Returns
The activity in the sales returns liability account was as follows (in thousands):

| Nine Months Ended
| September 28, 2024 |  | September 30, 2023
Balance at beginning of year | $22,402 |  | $25,594
Additions that reduce net sales | 69,391 |  | 82,718
Deductions from reserves | (72,105) |  | (85,300)
Balance at end of period | $19,688 |  | $23,012

9. Stock-based Compensation Expense
Total stock-based compensation expense was as follows (in thousands):

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Stock awards (1) | $774 |  | $(82) |  | 7,212 |  | $8,031
Stock options | 658 |  | 1,064 |  | 2,329 |  | 2,841
Total stock-based compensation expense (1) | 1,432 |  | 982 |  | 9,541 |  | 10,872
Income tax benefit | 285 |  | 118 |  | 2,004 |  | 1,305
Total stock-based compensation expense, net of tax | $1,147 |  | $864 |  | $7,537 |  | $9,567

___________________________
(1) Changes in stock-based compensation expense include the cumulative impact of the change in the expected achievements of certain performance
targets.
10. Profit Sharing and 401(k) Plan
Under the Company’s profit sharing and 401(k) plan, eligible employees may defer up to 50% of their compensation on a
pre-tax basis, subject to Internal Revenue Service limitations. Each pay period, the Company makes a contribution equal
to a percentage of the employee’s contribution. During the three months ended September 28, 2024 and
September 30, 2023, the Company’s contributions, net of forfeitures, were $1.9 million and $2.3 million, respectively and
during the nine months ended September 28, 2024 and September 30, 2023, were $5.1 million and $7.5 million,
respectively.

11 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
11. Net (Loss) Income per Common Share
The components of basic and diluted net (loss) income per share were as follows (in thousands, except per share
amounts):

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Net (loss) income | $(3,136) |  | $(2,318) |  | $(15,669) |  | $9,901
Reconciliation of weighted-average shares outstanding: |  |  |  |  |  |
Basic weighted-average shares outstanding | 22,643 |  | 22,479 |  | 22,588 |  | 22,412
Dilutive effect of stock-based awards | — |  | — |  | — |  | 146
Diluted weighted-average shares outstanding | 22,643 |  | 22,479 |  | 22,588 |  | 22,558
Net (loss) income per share – basic | $(0.14) |  | $(0.10) |  | $(0.69) |  | $0.44
Net (loss) income per share – diluted | $(0.14) |  | $(0.10) |  | $(0.69) |  | $0.44

For the three months ende d September 28, 2024 and September 30, 2023, and for the nine months ended
September 28, 2024, otherwise dilutive stock-based awards have been excluded from the calculation of diluted
weighted-average shares outstanding, as their inclusion would have had an anti-dilutive effect on our net loss per diluted
share. Additional potential dilutive stock-based awards totaling 1.2 million and 1.1 million for the three months ended
September 28, 2024 and September 30, 2023, respectively, and 1.3 million and 1.2 million for the nine months ended
September 28, 2024 and September 30, 2023, respectively, have been excluded from the diluted net (loss)/income per
share calculations because these stock-based awards were anti-dilutive.
12. Restructuring Costs
In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate
gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs
incurred in 2023, the Company incurred an additional $2.0 million and $14.4 million of restructuring costs during the
three and nine months ended September 28, 2024, respectively. Charges incurred related to this initiative were
comprised of contract termination costs, severance and employee-related benefits, professional fees and other, and
asset impairment charges and are included in the restructuring costs line in the Company’s condensed consolidated
statement of operations. The Company expects an additional $2 million to $3 million of restructuring costs to be i ncurred
through the remainde r of 2024, primarily due to lease contract termination costs. The following table provides a
summary of the Company’s restructuring costs during the during the three and nine months ended September 28, 2024:

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 28, 2024
Cash restructuring costs: |  |  |
Contract termination costs (1) | $300 |  | $4,483
Severance and employee-related benefits | 1,663 |  | 2,905
Professional fees and other | — |  | 4,494
Total cash restructuring costs | 1,963 |  | 11,882
Non-cash restructuring costs: |  |  |
Asset impairments (2) | — |  | 2,500
Total restructuring costs | $1,963 |  | $14,382

____________________
(1) Primarily comprised of lease termination costs.
(2) Primarily comprised of impairments of property and equipment.

12 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
The following table provides the activity in the Company’s restructuring related liabilities, which are included within
accounts payable, compensation and benefits and other current liabilities on the condensed consolidated balance sheet
(in thousands):

|  |  | Nine Months Ended
|  |  | September 28, 2024
Balance at the beginning of year |  |  | $8,720
Expenses |  |  | 11,882
Cash payments |  |  | (19,282)
Balance at the end of the period |  |  | $1,320

Since the initiation of cost reduction actions in the fourth quarter of 2023, the Company has recognized a cumulative
$30.1 million of restructuring costs, as follows (in thousands):

|  | Cumulative
|  | September 28, 2024
Cash restructuring costs: |  |
Contract termination costs (1) |  | $11,893
Severance and employee-related benefits |  | 7,871
Professional fees and other |  | 5,604
Total cash restructuring costs |  | 25,368
Non-cash restructuring costs: |  |
Asset impairments (2) |  | 4,742
Total restructuring costs |  | $30,110

____________________
(1)Primarily comprised of lease termination costs.
(2) Includes impairments of both lease right-of-use assets and property and equipment.
13. Commitments and Contingencies
Warranty Liabilities
The activity in the accrued warranty liabilities account was as follows (in thousands):

| Nine Months Ended
| September 28, 2024 |  | September 30, 2023
Balance at beginning of period | $8,503 |  | $8,997
Additions charged to costs and expenses for current-year sales | 9,981 |  | 12,327
Deductions from reserves | (11,546) |  | (12,543)
Changes in liability for pre-existing warranties during the current year, including expirations | 511 |  | 40
Balance at end of period | $7,449 |  | $8,821

13 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
Legal Proceedings
The Company is involved from time to time in various legal proceedings arising in the ordinary course of its business,
including primarily commercial, product liability, employment and intellectual property claims. In accordance with U.S.
generally accepted accounting principles, the Company records a liability in its condensed consolidated financial
statements with respect to any of these matters when it is both probable that a liability has been incurred and the
amount of the liability can be reasonably estimated. If a material loss is reasonably possible but not known or probable,
and may be reasonably estimated, the estimated loss or range of loss is disclosed. With respect to currently pending
legal proceedings, the Company has not established an estimated range of reasonably possible material losses either
because it believes that is has valid defenses to claims asserted against it, the proceeding has not advanced to a stage of
discovery that would enable it to establish an estimate, or the potential loss is not material. The Company currently does
not expect the outcome of pending legal proceedings to have a material effect on its condensed consolidated results of
operations, financial position or cash flows. Litigation, however, is inherently unpredictable, and it is possible that the
ultimate outcome of one or more claims asserted against the Company could adversely impact its condensed
consolidated results of operations, financial position or cash flows. The Company expenses legal costs as incurred.
Purported Class Action Complaint
On September 27, 2024, a purported customer served a putative class action complaint on behalf of themself and a
putative class of California consumers against Sleep Number in the United States District Court for the Eastern District of
California alleging that Sleep Number’s beds are perpetually on sale in violation of California law. The Plaintiff seeks
injunctive relief, damages, and attorneys fees. Sleep Number does not believe the Plaintiff’s claims have merit and
intends to vigorously defend this matter.
Purported Class Action Complaint
On December 15, 2023, a former Field Services team member filed a purported class action Complaint in the Superior
Court of California, County of Santa Clara, alleging violations of California’s meal and rest break law and additional wage
and hour derivative claims under the California Labor Code. While the representative plaintiff was in the Field Services
workforce, the Complaint does not limit the purported plaintiff class to that group, but rather extends to all non-exempt
Sleep Number employees in the state. The plaintiff alleges that Sleep Number failed to provide compliant meal or rest
breaks, failed to pay wages owed due to alleged off the clock work, failed to pay overtime, minimum wage and wages
due at termination, thus resulting in inaccurate wage statements, all in violation of California law. The Complaint seeks
damages in the form of unpaid regular and premium wages, statutory penalties, pre-judgment and post-judgment
interest, plaintiffs’ attorneys’ fees and costs. On February 22, 2024, the plaintiff filed a related lawsuit in the same county
alleging violations of a broad range of California Labor Code wage and hour violations under the state’s Private Attorney
General Act (PAGA), including the same meal and rest break, and wage and hour, violations as appear in the purported
class action.
The Court dismissed the class action complaint with prejudice. The Court sua sponte stayed the PAGA collective action
and the individual plaintiff must prove his claims in arbitration before the stay is lifted. Given the developments in these
proceedings, the matter no longer rises to the level of disclosure in Sleep Number’s periodic reports.
Shareholder Class Action Complaints
On December 14, 2021, purported Sleep Number shareholder, Steamfitters Local 449 Pension & Retirement Security
Funds (Steamfitters), filed a putative class action complaint in the United States District Court for the District of
Minnesota (the District of Minnesota) on behalf of all purchasers of Sleep Number common stock between February 18,
2021 and July 20, 2021, inclusive, against Sleep Number, Shelly Ibach and David Callen, the Company’s former
Executive Vice President and Chief Financial Officer. Steamfitters alleges material misstatements and omissions in certain
of Sleep Number’s public disclosures during the purported class period, in violation of Sections 10(b) and 20(a) of the
Securities Exchange Act of 1934, as amended (the Exchange Act). The complaint seeks, among other things, unspecified
monetary damages, reasonable costs and expenses and equitable/injunctive or other relief as deemed appropriate by
the District of Minnesota.

14 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Table of Contents
SLEEP NUMBER CORPORATION
AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(unaudited)
On February 14, 2022, a second purported Sleep Number shareholder, Ricardo Dario Schammas, moved for
appointment as lead plaintiff in the action. On March 24, 2022, the District of Minnesota heard argument on Schammas’s
motion, and subsequently appointed Steamfitters and Schammas as Co-Lead Plaintiffs (together, Co-Lead Plaintiffs). On
July 19, 2022, Co-Lead Plaintiffs filed a consolidated amended complaint, which, like the predecessor complaint, asserts
claims against Sleep Number, Shelly Ibach, and David Callen under Sections 10(b) and 20(a) of the Exchange Act. Co-
Lead Plaintiffs purport to assert these claims on behalf of all purchasers of Sleep Number common stock between
February 18, 2021 and July 20, 2021. On September 19, 2022, Defendants moved to dismiss the consolidated amended
complaint, which motion was heard by the Court on January 17, 2023. On July 10, 2023, the Court issued an order
dismissing the Plaintiffs’ consolidated amended complaint with prejudice.
Shareholder Derivative Complaint
On May 12, 2022, Gwendolyn Calla Moore, as the appointed representative of purported Sleep Number shareholder
Matthew Gelb, filed a derivative action (the Derivative Action) in the District of Minnesota against Jean-Michel Valette,
Shelly Ibach, Barbara Matas, Brenda Lauderback, Daniel Alegre, Deborah Kilpatrick, Julie Howard, Kathleen Nedorostek,
Michael Harrison, Stephen Gulis, Jr., David Callen, and Kevin Brown. Moore purports to assert claims on behalf of Sleep
Number for breaches of fiduciary duty, waste, and contribution under Sections 10(b) and 21(d) of the Exchange Act.
Moore’s allegations generally mirror those asserted in the securities complaint described above. The Moore complaint
seeks damages in an unspecified amount, disgorgement, interest, and costs and expenses, including attorneys’ and
experts’ fees.
On September 13, 2022, the District of Minnesota entered a joint stipulation staying all proceedings in the Derivative
Action pending the outcome of any motion to dismiss the Steamfitters consolidated amended complaint. On July 10,
2023, the District of Minnesota in the Steamfitters case dismissed the consolidated amended complaint with prejudice,
as noted above. The Plaintiff in the Derivative Action subsequently moved the Court to voluntarily dismiss its Complaint
and on January 22, 2024, the District of Minnesota dismissed the Derivative Action without prejudice.
Stockholder Demand
On March 25, 2022, Sleep Number received a shareholder litigation demand (the “Demand”), requesting that the Board
investigate the allegations in the Steamfitters complaint and pursue claims on Sleep Number’s behalf based on those
allegations. On May 12, 2022, the Board established a special litigation committee to investigate the demand.
On October 5 and October 12, 2022, Sleep Number received two additional shareholder litigation demands, which
adopted and incorporated the allegations and requests in the Demand. Both of these additional litigation demands were
referred to the special litigation committee.
Subsequently, the special litigation committee determined that it would not be in the best interests of the Company and
its shareholders to take the actions requested in the demands and, thus, rejected the demands in their entirety.

15 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide
a reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of
management on its financial condition, results of operations, liquidity and certain other factors that may affect the
Company’s future results. MD&A is presented in seven sections:
•Forward-Looking Statements and Risk Factors
•Business Overview
•Results of Operations
•Liquidity and Capital Resources
•Non-GAAP Data Reconciliations
•Off-Balance-Sheet Arrangements and Contractual Obligations
•Critical Accounting Policies
Forward-looking Statements and Risk Factors
The discussion in this Quarterly Report on Form 10-Q contains certain forward-looking statements that relate to
future plans, events, financial results or performance. You can identify forward-looking statements by those that
are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or
the negative of these or similar terms. These statements are subject to certain risks and uncertainties that could
cause actual results to differ materially from the Company’s historical experience and its present expectations or
projections. These risks and uncertainties include, among others:
•Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;
•Increases in interest rates, which have increased the cost of servicing the Company’s indebtedness;
•Availability of attractive and cost-effective consumer credit options;
•Ability to achieve savings and efficiencies from cost savings plans related to business restructuring actions and to
avoid unexpected adverse effects;
•Dependence on, and ability to maintain working relationships and favorable contractual terms with key suppliers and
third parties;
•Fluctuations in commodity costs or third-party delivery or logistics costs and other inflationary pressures;
•Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,
labor challenges, foreign currency fluctuations, inflation, and climate or other disasters, and resulting supply
shortages and production and delivery delays and disruptions;
•Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages, as well as
carrying excess levels of inventory for various products from time to time, which may leave the Company vulnerable
to inventory obsolescence and write-downs;
•The effectiveness of the Company’s marketing strategy and promotional efforts;
•The execution of the Company’s Total Retail distribution strategy;
•Ability to achieve and maintain high levels of product quality and to improve and expand the product line;
•Ability to protect the Company’s technology, trademarks, and brand and the adequacy of its intellectual property
rights;
•Ability to effectively compete;
•Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,
assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer
service operations;
•Ability to comply with existing and changing government regulations and laws;
•Pending or unforeseen litigation and the potential for associated adverse publicity;
•The adequacy of the Company’s and third-party information systems and costs and disruptions related to upgrading
or maintaining these systems;

16 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
•The Company’s ability to identify and withstand cyber threats that could compromise the security of its systems,
result in a data breach or business disruption;
•Risks associated with advancements in or adoption of artificial intelligence technologies;
•The Company’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and
effective personnel;
•The volatility of the Company’s stock, its removal from various stock indices, and the potential negative effects of
shareholder activism or of changes in coverage by securities analysts;
•Environmental, social and governance risks, including increasing regulation and stakeholder expectations; and
•The Company’s ability to adapt to climate change and readiness for legal or regulatory responses thereto.
Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk
Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent
Quarterly Reports on Form 10-Q.
The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this
Quarterly Report on Form 10-Q.
Business Overview
Sleep Number is a wellness technology company and market leader in the design, manufacturing, marketing and
distribution of innovative sleep solutions. The Company’s purpose is to improve the health and wellbeing of society
through higher quality sleep; to date, it has improved the lives of nearly 16 million people. Sleep Number’s Smart
Sleepers benefit from individualized sleep experiences, night after night, and are experiencing the physical, mental and
emotional benefits of life-changing sleep.
Sleep Number’s life-changing, differentiated smart beds combine physical and digital innovations, integrating
unparalleled physical comfort with a proprietary technology platform. The smart beds offer the Company’s signature
firmness adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep needs of each
individual; “sense and do” technology uses the sensed data to automatically adjust the smart bed to keep the sleeper
comfortable throughout the night. Active temperature balancing technology supports the ideal climate for both sleepers
and solves a prevalent sleep challenge. Additionally, the smart beds are an exceptional value, with personalized sleep
insights delivered daily, new features regularly added to all smart beds through over-the-air updates, at a range of good,
better and best price points. Sleep Number® smart beds provide unique features, benefits and comfort designed for
improved sleep health and wellness for both sleepers.
The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized sleep
wellness platform, an ecosystem of almost 3 mil lion highly engaged Smart Sleepers, a vertically integrated operating
model, and a culture of individuality, with an ambitious vision to become one of the world’s most beloved brands. Sleep
Number’s exclusive distribution supports lifelong customer relationships – through digital and in-store touchpoints – to
provide an exceptional brand experience. The Company’s more than 29 billion hours of longitudinal sleep data enables
strategic collaborations with world-leading health and research institutions, including Mayo Clinic and American Cancer
Society. And Sleep Number’s 3,700 purpose-driven team members are dedicated to the Company’s mission of
improving lives by individualizing sleep experiences.
In the fourth quarter of 2023, Sleep Number began transforming its operating model for greater financial resilience
across a range of economic environments. These cost improvement actions are broad-based. The Company’s
transformation progress, combined with rigorous execution of their differentiated strategy, positions it - when market
growth returns - to capitalize on their innovation leadership, accelerate profitable growth, generate strong cash flow, and
deliver increased value for shareholders. The Company generates revenue by marketing and selling its innovative smart
beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch
points including Stores, Online, Phone, and Chat (Total Retail).

17 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Results of Operations
Quarterly and Year-to-Date Results
Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including
increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return
rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/
closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new
product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity
costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,
consumer sentiment and general economic conditions. The extent to which these external factors will impact the
Company’s business and its consolidated financial results will depend on future developments, which are highly
uncertain and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that
may be achieved for any future period.
Highlights
Financial highlights for the three months ended September 28, 2024 were as follow s:
•Net sales for the three months ended September 28, 2024 of $427 million decreased 10% from $473 million for the
same period one year ago due to t he ongoing weakness in the mattress industry and consumers continuing to
scrutinize their spending.
•The net sales change resulted from a 9% comparable sales decrease in Total Retail. For additional details, see the
components of total net sales change on page 19.
•Average sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a
trailing twelve-month basis for the period ended September 28, 2024 totaled $2.7 million, compared with $3.0
million for the same period last year.
•Operating income for the three months ended September 28, 2024 was $8 million, compared with $5 million in the
prior-year period. The $3 million in crease in operating income was driven by a $15 million reduction in operating
expenses and a 3.4 ppt. increase in the gross profit rate, offset by lower net sales. Operating expenses for the three
months ended September 28, 2024 included $2 million of restructuring costs.
•Adjusted EBITDA for the three months ended September 28, 2024 was $28 million, compared to $25 million in the
prior-year period as ongoing gross margin improvements and cost reduction actions partially offset the year-over-
year net sales decline.
•Gross profit rate of 60.8% was 3.4 ppt. higher than the prior-year period. The increase was primarily due to year-
over-year product cost reductions through value engineering and ongoing supplier negotiations and favorable
product mix. See the gross profit discussion on page 20 for additional details.
•The $15 million year-over-year reduction in the Company’s operating expenses was due to lower sales and
marketing and research and development expenses, partly offset by $2 million of restructuring costs.
•Net loss for the three months ended September 28, 2024 was $3 million, compared with a net loss of $2 million for
the same period one year ago. Net loss per diluted share was $0.14, compared with a net loss per diluted share of
$0.10 for the comparable period one year ago.
•The Company’s adjusted return on invested capital (Adjusted ROIC) was 4.5% on a trailing twelve-month basis for
the period ended September 28, 2024, compared with 14.9% for the comparable period one year ago.
•The Company generated $51 million in cash from operating activities for the nine months ended September 28,
2024, compared with $32 million for the same period one year ago.
•Free cash flow provided $34 million for the nine months ended September 28, 2024, compared with using $16
million for the same period one year ago.
•As of September 28, 2024, the Company had $517 million of borrowings under its revolving credit facility.

18 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.
Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Net sales | $426.6 |  | 100.0% |  | $472.6 |  | 100.0% |  | $1,305.5 |  | 100.0% |  | $1,458.0 |  | 100.0%
Cost of sales | 167.1 |  | 39.2% |  | 201.5 |  | 42.6% |  | 528.3 |  | 40.5% |  | 612.3 |  | 42.0%
Gross profit | 259.5 |  | 60.8% |  | 271.1 |  | 57.4% |  | 777.2 |  | 59.5% |  | 845.6 |  | 58.0%
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing | 205.5 |  | 48.2% |  | 221.1 |  | 46.8% |  | 596.4 |  | 45.7% |  | 649.4 |  | 44.5%
General and administrative | 33.1 |  | 7.8% |  | 31.9 |  | 6.8% |  | 111.7 |  | 8.6% |  | 111.1 |  | 7.6%
Research and development | 10.6 |  | 2.5% |  | 12.6 |  | 2.7% |  | 34.6 |  | 2.7% |  | 42.5 |  | 2.9%
Restructuring costs | 2.0 |  | 0.5% |  | — |  | 0.0% |  | 14.4 |  | 1.1% |  | — |  | 0.0%
Total operating expenses | 251.1 |  | 58.9% |  | 265.7 |  | 56.2% |  | 757.1 |  | 58.0% |  | 803.1 |  | 55.1%
Operating income | 8.4 |  | 2.0% |  | 5.4 |  | 1.1% |  | 20.1 |  | 1.5% |  | 42.5 |  | 2.9%
Interest expense, net | 12.1 |  | 2.8% |  | 11.0 |  | 2.3% |  | 36.6 |  | 2.8% |  | 30.0 |  | 2.1%
(Loss) income before income taxes | (3.6) |  | (0.8%) |  | (5.6) |  | (1.2%) |  | (16.5) |  | (1.3%) |  | 12.5 |  | 0.9%
Income tax (benefit) expense | (0.5) |  | (0.1%) |  | (3.3) |  | (0.7%) |  | (0.9) |  | (0.1%) |  | 2.6 |  | 0.2%
Net (loss) income | $(3.1) |  | (0.7%) |  | $(2.3) |  | (0.5%) |  | $(15.7) |  | (1.2%) |  | $9.9 |  | 0.7%
Net (loss) income per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic | $(0.14) |  |  |  | $(0.10) |  |  |  | $(0.69) |  |  |  | $0.44 |  |
Diluted | $(0.14) |  |  |  | $(0.10) |  |  |  | $(0.69) |  |  |  | $0.44 |  |
Weighted-average number of common shares: |  |  |  |  |  |  |  |  |  |  |  |
Basic | 22.6 |  |  |  | 22.5 |  |  |  | 22.6 |  |  |  | 22.4 |  |
Diluted | 22.6 |  |  |  | 22.5 |  |  |  | 22.6 |  |  |  | 22.6 |  |

The percentage of total net sales, by dollar volume, was as follows:

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Retail stores | 87.8% |  | 86.6% |  | 87.9% |  | 87.1%
Online, phone, chat and other | 12.2% |  | 13.4% |  | 12.1% |  | 12.9%
Total Company | 100.0% |  | 100.0% |  | 100.0% |  | 100.0%

19 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

The components of total net sales change, including comparable net sales changes, were as follows:

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Sales change rates: |  |  |  |  |  |  |
Retail comparable-store sales (1) | (7%) |  | (14%) |  | (9%) |  | (11%)
Online, phone and chat | (18%) |  | (14%) |  | (17%) |  | (13%)
Total Retail comparable sales change (1) | (9%) |  | (14%) |  | (10%) |  | (11%)
Net opened/closed stores and other | (1%) |  | 1% |  | 0% |  | 1%
Total Company | (10%) |  | (13%) |  | (10%) |  | (10%)

___________________________
(1)Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned
within the same shopping center remain in the comparable-store base.
Other sales metrics were as follows:

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Average sales per store (1) (in thousands) | $2,670 |  | $2,952 |  |  |  |
Average sales per square foot (1) | $863 |  | $963 |  |  |  |
Stores > $2 million in net sales (2) | 60% |  | 67% |  |  |  |
Stores > $3 million in net sales (2) | 20% |  | 27% |  |  |  |
Average revenue per smart bed unit (3) | $5,771 |  | $5,640 |  | $5,778 |  | $5,822

___________________________
(1)Trailing-twelve months Total Retail comparable sales per store open at least one year.
(2)Trailing-twelve months for stores open at least one year (excludes online, phone and chat sales).
(3)Represents Total Retail net sales divided by Total Retail smart bed units.
The number of retail stores operating was as follows:

| Three Months Ended |  | Nine Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Beginning of period | 646 |  | 672 |  | 672 |  | 670
Opened | 1 |  | 8 |  | 11 |  | 27
Closed | (4) |  | (2) |  | (40) |  | (19)
End of period | 643 |  | 678 |  | 643 |  | 678

20 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Comparison of Three Months Ended September 28, 2024 with Three Months Ended September 30, 2023
Net sales
Net sales for the three months ended September 28, 2024 of $427 million decreased 10% from $473 million for the
same period one year ago due to t he ongoing weakness in the mattress industry and consumers continuing to scrutinize
their spending.
The net sales change consisted primarily of an 9% comparable sales decrease in Total Retail.
The $46 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a
$27 million decrease in Retail comparable net sales; (ii) a $12 million decrease from online, phone and chat; and (iii) a $7
million decrease from net store closings and other. Total Retail smart bed unit sales decreased 12% compared with the
prior year. Total Retail average revenue per smart bed unit increased by 2% to $5,771, compared with $5,640 in the
prior-year period.
Gross profit
Gross profit of $260 million for the three months ended September 28, 2024 decreased by $12 million, or 4%, compared
with $271 million for the same period one year ago. The gross profit rate increased to 60.8% of net sales for the three
months ended September 28, 2024, compared with 57.4% for the prior-year comparable period.
The current-year gross profit rate increase of 3.4 ppt. was mainly due to: (i) year-over-year product cost reductions
through value engineering and ongoing supplier negotiations, increased the rate by 1.7 ppt; (ii) a favorable product mix,
increased the rate by 1.0 ppt; (iii) and efficiency gains in our home delivery and logistics operations, increased the rate by
0.7 pp t. In addition, the gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including
changes in warranty expenses, return and exchange costs, manufacturing and supply chain operations and performance-
based incentive compensation.
Sales and marketing expenses
Sales and marketing expenses for the three months ended September 28, 2024 were $205 million, or 48.2% of net sales,
compared with $221 million, or 46.8% of net sales, for the same period one year ago. The current-year sales and
marketing expenses rate increase of 1.4 ppt. was primarily due to the deleveraging impact of an 10% net sales decline
offset by a 7% decrease in expenses including a 4% lower media spend.
General and administrative expenses
General and administrative (G&A) expenses totaled $33 million, or 7.8% of net sales, for the three months ended
September 28, 2024, compared with $32 million, or 6.8% of net sales, in the prior-year period. The $1 million increase in
G&A expenses consisted mainly of: (i) a $1.9 million year-over-year increase in company-wide, performance-based
incentive compensation; offset by (ii) a $0.6 million decrease in employee compensation on lower headcount; and (iii) a
$0.2 million decrease in other miscellaneous expenses. The G&A expenses rate increased by 1.0 ppt. in the current-year
period, compared with the same period one year ago due to the items discussed above offset by the deleveraging
impact of lower net sales.
Research and development expenses
Research and development (R&D) expenses decreased to $11 million for the three months ended September 28, 2024,
compared with $13 million with the same period last year primarily due to lower headcount and outside services. While
the Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained
environment.
Interest expense, net
Interest expense, net increased to $12 million for the three months ended September 28, 2024, compared with $11
million for the same period one year ago. The $1 million increase was mainly driven by a higher weighted-average
interest rate compared with the same period one year ago.

21 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Restructuring Costs
In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate
gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs
incurred in 2023, the Company incurred an additional $2.0 million and $14.4 million of restructuring costs during the
three and nine months ended September 28, 2024, respectively. Charges incurred related to this initiative were
comprised of contract termination costs, severance and employee-related benefits, professional fees and other, and
asset impairment charges and are included in the restructuring costs line in the Company’s consolidated statement of
operations. The Company expects an additional $2 million to $3 million of restructuring costs to be incurred through the
remainder of 2024, primarily due to lease contract termination costs.
Income tax (benefit) expense
Income tax benef it totaled $0.5 million for the three months ended September 28, 2024, compared with income tax
benefit of $3 million for the same period last year. The change in income tax benefit was primarily due to the impact of
the loss before income tax levels.
Comparison of Nine Months Ended September 28, 2024 with Nine Months Ended September 30, 2023
Net sales
Net sales for the nine months ended September 28, 2024 decreased by $152 million, or 10%, to $1.3 billion, compared
with $1.5 billion for the same period one year ago due to t he ongoing weakness in the mattress industry and consumers
continuing to scrutinize their spending.
The net sales decrease consisted primarily of an 10% comparable sales decrease in Total Retail. For additional details,
see the components of total net sales change on page 19.
The $152 million net sales decrease compared with the same period one year ago was comprised of the following: (i) an
$112 million decrease in Retail comparable net sales; (ii) a $31 million decrease in online, phone and other sales; and (iii)
a $9 million decrease resulting from net store closings. Total smart bed unit sales declined 10% compared with the same
period one year ago. Average revenue per smart bed unit in Total Retail decreased by 1% to $5,778, compared with
$5,822 in the prior-year period.
Gross profit
Gross profit of $777 million for the nine months ended September 28, 2024 decreased by $68 million, or 8%, compared
with $846 million for the same period one year ago. The gross profit rate increased to 59.5% of net sales for the nine
months ended September 28, 2024, compared to 58.0% in the prior-year comparable period.
The current-year gross profit rate increase of 1.5 ppt. was impacted by: (i) year-over-year product cost reductions
through value engineering and ongoing supplier negotiations, increased the rate by 1.1 ppt (ii) favorable pricing actions
taken over the last twelve months increased the rate by 1.0 ppt; (iii) efficiency gains in home delivery and logistics
operations, increased the rate by 0.7 ppt; partially offset by (iv) p roduct mix of FlexFit smart adjustable bases, which
pressured the rate by 1.0 ppt; and (v) l ower delivered smart bed volume deleveraged the rate by 0.2 ppt. In addition, the
gross profit rate may fluctuate from quarter to quarter due to a variety of other factors, including changes in warranty
expenses, manufacturing and supply chain operations and performance-based incentive compensation.
Sales and marketing expenses
Sales and marketing expenses for the nine months ended September 28, 2024 were $596 million, or 45.7% of net sales,
compared with $649 million, or 44.5% of net sales, for the same period one year ago. The current-year sales and
marketing expenses rate increase of 1.2 ppt. was primarily due to deleveraging impact of a 10% net sales decline offset
by a 8% decrease in expenses including 6% lower media spend.

22 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

General and administrative expenses
General and administrative (G&A) expenses totaled $112 million, or 8.6% of net sales, for the nine months
ended September 28, 2024, compared with $111 million, or 7.6% of net sales, in the prior-year period. The $1
million increase in G&A expenses consisted of: (i) a $2.6 million year-over-year increase in company-wide, performance-
based incentive compensation; (ii) a $0.8 million increase in technology investments; (iii) an increase in miscellaneous
other expenses of $3.1 million, which benefited during the same period one year ago from legal and insurance
settlements of $1.8 million; largely offset by (iv) a $4.4 million reduction in employee compensation on lower headcount;
and (v) a $1.1 million decrease in other occupancy expenses. The G&A expenses rate increased by 1.0 ppt. in the
current-year period, compared with the same period one year ago due to the deleveraging impact of the 10% net sales
decrease.
Research and development expenses
Research and development (R&D) expenses decreased by 19% to $35 million for the nine months ended September 28,
2024, compared with $43 million for the same period one year ago on lower outside services and headcount. While the
Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained
environment.
Interest expense, net
Interest expense, net increased to $37 million for the nine months ended September 28, 2024, compared with $30
million for the same period one year ago. The $7 million increase was mainly driven by a higher weighted-average
interest rate compared with the same period one year ago.
Restructuring Costs
In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate
gross margin initiatives, and recognized $15.7 million of restructuring costs in that quarter. In addition to the costs
incurred in 2023, the Company incurred $14.4 million of restructuring costs in the first nine months of 2024. Charges
incurred related to this initiative were comprised of contract termination costs, severance and employee-related benefits,
professional fees and other, and asset impairment charges and are included in the restructuring costs line in the
Company’s consolidated statement of operations. The Company expects an additional $2 million to $3 million of
restructuring costs to be incurred through the remainder of 2024, primarily due to lease contract termination costs.
Income tax (benefit) expense
Income tax benefit totaled $0.9 million for the nine months ended September 28, 2024, compared with income tax
expense of $3 million last year. The change in income tax expense was primarily due to the change in (loss) income
before income taxes levels and the impact of discrete tax expenses. Discrete tax expense, primarily stock-based
compensation tax shortfalls, was $2.6 million f or the nine months ended September 28, 2024, compared to $1.1 million
for the same period last year.
Liquidity and Capital Resources
Managing liquidity and capital resources is an important part of the Company’s commitment to deliver superior
shareholder value over time.
The Company’s primary sources of liquidity are cash flows provided by operating activities and cash available under its
$680 million revolving credit facility, as amended. As of September 28, 2024, the Company does not have any off-
balance sheet financing other than its $7 million in outstanding letters of credit. The cash generated from ongoing
operations and cash available under the revolving credit facility are expected to be adequate to maintain operations,
and fund anticipated expansion, strategic initiatives and contractual obligations such as lease payments and capital
commitments for new retail stores for the foreseeable future.
Cash and cash equivalents totaled $1.6 million and $2.5 million at September 28, 2024 and December 30, 2023,
respectively. Significant changes in cash and cash equivalents during the nine months ended September 28, 2024
primarily consisted of $51 million of cash provided by operating activities, offset by a $31 million decrease in short-term

23 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

borrowings, $17 million of cash used to purchase property and equipment, and $3 million of cash used to issue notes
receivable.
The following table summarizes cash flows (in millions). Amounts may not add due to rounding differences:

| Nine Months Ended
| September 28, 2024 |  | September 30, 2023
Total cash provided by (used in): |  |  |
Operating activities | $50.8 |  | $31.8
Investing activities | (20.0) |  | (49.3)
Financing activities | (31.8) |  | 16.6
Net decrease in cash and cash equivalents | $(0.9) |  | $(0.9)

Net cash provided by operating activities for the nine months ended September 28, 2024 was $51 million, compared
with $32 million for the nine months ended September 30, 2023. Significant components of the year-over-year change in
cash provided by operating activities included: (i) a $25 million fluctuation in inventory due to lower sales volumes and
operational improvements; (ii) a $22 million fluctuation in customer prepayments; and (iii) a $8 million fluctuation in
accrued compensation and benefits; partially offset by (iii) a $26 million decrease in net income for the nine months
ended September 28, 2024 compared with the nine months ended September 30, 2023; and (iv) a $9 million fluctuation
in other accruals and liabilities.
Net cash used in investing activities for the nine months ended September 28, 2024 was $20 million, compared with $49
million for the nine months ended September 30, 2023. Cash used to purchase property and equipment was $17 million
for the nine months ended September 28, 2024, compared with $48 million for the same period one year ago. In
addition, the Company issued $3 million of notes receivable during the nine months ended September 28, 2024.
Net cash used in financing activities was $32 million for the nine months ended September 28, 2024, compared with net
cash provided by financing activities of $17 million for the same period last year. Short-term borrowings decreased by
$31 million during the current-year period due to a $23 million decrease in borrowings under the revolving credit facility
to $517 million and a $8 million decrease in book overdrafts, which are included in the net change in short-term
borrowings. During the nine months ended September 28, 2024, the Company repurchased $1 million of its stock
compared with $4 million (based on settlement dates, in connection with the vesting of employee restricted stock
awards) during the same period one year ago. The Company made no share repurchases under its Board-approved
share repurchase program in either period.
In the second quarter of fiscal 2022, the Company suspended share repurchases under its Board-approved share
repurchase program. At September 28, 2024, there was $348 million remaining authorization under the Board-approved
$600 million share repurchase program. There is no expiration date governing the period over which the Company can
repurchase shares.
At September 28, 2024, the Company had $517 million of borrowings under its revolving credit facility, $7 million in
outstanding letters of credit and net liquidity available under the credit facility of $156 million. Total availability under its
revolving credit facility was $680 million, which amortizes by $2.5 million per quarter through December 2026. A t
September 28, 2024, the Company’s leverage ratio as defined in the credit agreement was 4.2 x versus the permissible
net leverage ratio of 5.0x, the weighted-average interest rate on borrowings under the credit facility was 8.2% and the
Company was in compliance with all financial covenants.

24 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
Non-GAAP Data Reconciliations
Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)
The Company defines earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net income
plus: income tax expense, interest expense, depreciation and amortization, stock-based compensation, restructuring
costs and asset impairments. Management believes Adjusted EBITDA is a useful indicator of its financial performance
and its ability to generate cash from operating activities. The Company’s definition of Adjusted EBITDA may not be
comparable to similarly titled definitions used by other companies. The table below reconciles Adjusted EBITDA, which
is a non-GAAP financial measure, to the comparable GAAP financial measure.
Adjusted EBITDA calculations are as follows (in thousands):

| Three Months Ended |  | Trailing-Twelve Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Net (loss) income | $(3,136) |  | $(2,318) |  | $(40,857) |  | $4,471
Income tax (benefit) expense | (489) |  | (3,253) |  | (7,966) |  | 1,346
Interest expense | 12,057 |  | 10,958 |  | 49,313 |  | 37,641
Depreciation and amortization | 15,859 |  | 18,200 |  | 67,335 |  | 72,338
Stock-based compensation | 1,432 |  | 982 |  | 13,523 |  | 15,511
Restructuring costs | 1,963 |  | — |  | 30,110 |  | —
Asset impairments | — |  | 292 |  | 198 |  | 491
Adjusted EBITDA | $27,686 |  | $24,861 |  | $111,656 |  | $131,798

Free Cash Flow
The Company’s “free cash flow” data is considered a non-GAAP financial measure and is not in accordance with, or
preferable to, “net cash provided by operating activities,” or GAAP financial data. However, the Company is providing
this information as it believes it facilitates analysis for investors and financial analysts.
The following table summarizes free cash flow calculations (in thousands):

| Nine Months Ended |  | Trailing-Twelve Months Ended
| September 28, 2024 |  | September 30, 2023 |  | September 28, 2024 |  | September 30, 2023
Net cash provided by (used in) operating activities | $50,824 |  | $31,816 |  | $9,980 |  | $(12,168)
Subtract: Purchases of property and equipment | 17,218 |  | 48,022 |  | 26,252 |  | 64,668
Free cash flow | $33,606 |  | $(16,206) |  | $(16,272) |  | $(76,836)

25 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
Non-GAAP Data Reconciliations (continued)
Return on Invested Capital (Adjusted ROIC)
Adjusted ROIC is a financial measure the Company uses to determine how efficiently it deploys its capital. It quantifies
the return the Company earns on its adjusted invested capital. Management believes Adjusted ROIC is also a useful
metric for investors and financial analysts. The Company computes Adjusted ROIC as outlined below. Its definition and
calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other
companies.
The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested
capital, which are non-GAAP financial measures, to the comparable GAAP financial measures (in thousands):

| Trailing-Twelve Months Ended
| September 28, 2024 |  | September 30, 2023
Adjusted net operating profit after taxes (Adjusted NOPAT) |  |  |
Operating income | $490 |  | $43,458
Add: Operating lease expense (1) | 27,371 |  | 27,497
Less: Income taxes (2) | (5,474) |  | (1,168)
Adjusted NOPAT | $22,387 |  | $69,787
Average adjusted invested capital |  |  |
Total deficit | $(448,784) |  | $(420,687)
Add: Long-term debt (3) | 516,761 |  | 488,338
Add: Operating lease obligations (4) | 401,153 |  | 439,722
Total adjusted invested capital at end of period | $469,130 |  | $507,373
Average adjusted invested capital (5) | $502,494 |  | $469,782
Adjusted return on invested capital (Adjusted ROIC) (6) | 4.5% |  | 14.9%

___________________________
(1) Represents the interest expense component of lease expense included in the Company’s financial statements under ASC 842, Leases.
(2) Reflects annual effective income tax rates, before discrete adjustments, of 19.6% and 1.6% for September 28, 2024 and September 30, 2023,
respectively.
(3) Long-term debt includes existing finance lease liabilities.
(4) Reflects operating lease liabilities included in the Company’s financial statements under ASC 842.
(5) Average adjusted invested capital represents the average of the last five fiscal quarters’ ending adjusted invested capital balances.
(6) Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.
Note - the Company’s adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable
to, GAAP financial data. However, the Company is providing this information as it believe it facilitates analysis of the Company's financial performance
by investors and financial analysts.
GAAP - generally accepted accounting principles in the U.S.
Critical Accounting Policies
The Company discusses its critical accounting policies and estimates in Management’s Discussion and Analysis of
Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the fiscal year ended
December 30, 2023. There were no significant changes in the Company’s critical accounting policies since the end of
fiscal 2023.

26 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is exposed to changes in market-based short-term interest rates that will impact net interest expense. If
overall interest rates were one percentage point higher than current rates, annual net income would decrease by
$4.2 million based on the $517 million of borrowings under the credit facility at September 28, 2024. The Company does
not manage the interest-rate volatility risk of borrowings under the credit facility through the use of derivative
instruments.
ITEM 4. CONTROLS AND PROCEDURES
Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), that are
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under
the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is
accumulated and communicated to the Company’s management, including its principal executive officer and principal
financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure. The Company’s management, with the participation of its principal executive officer and principal financial
officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as
of the end of the period covered by this quarterly report. Based on this evaluation, its principal executive officer and
principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of the end
of the period covered by this quarterly report.
Changes in Internal Control
There were no changes in the Company’s internal control over financial reporting during the fiscal quarter ended
September 28, 2024, that have materially affected, or are reasonably likely to materially affect, the Company’s internal
control over financial reporting.

27 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
PART II: OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The Company’s legal proceedings are discussed in Note 13 – Commitments and Contingencies, Legal Proceedings, in
the Notes to Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
ITEM 1A. RISK FACTORS
The Company’s business, financial condition and operating results are subject to a number of risks and uncertainties,
including both those that are specific to the Company’s business and others that affect all businesses operating in a
global environment. Investors should carefully consider the information in this report under the heading, Management’s
Discussion and Analysis of Financial Condition and Results of Operations, and also the information under the heading,
Risk Factors, in the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q. The risk factors discussed in the Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q
including this Quarterly Report on Form 10-Q do not identify all risks that the Company faces because its business
operations could also be affected by additional risk factors that are not presently known to the Company or that it
currently considers to be immaterial to its operations.

28 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS, AND ISSUER PURCHASES OF
EQUITY SECURITIES
(a) – (b) Not applicable.
(c) Issuer Purchases of Equity Securities

Period |  | Total Number of Shares Purchased(1)(2) |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(3)
June 30, 2024 through July 27, 2024 |  | 67 |  | $8.63 |  | — |  | $348,071,000
July 28, 2024 through August 24, 2024 |  | 3,687 |  | $12.13 |  | — |  | $348,071,000
August 25, 2024 through September 28, 2024 |  | 4,232 |  | $16.71 |  | — |  | $348,071,000
Total |  | 7,986 |  | $14.53 |  | — |  | $348,071,000

___________________________
(1)The Company did not purchase any shares under its Board-approved $600 million share repurchase program (effective April 4, 2021), during the
three months ended September 28, 2024.
(2)In connection with the vesting of employee restricted stock grants, the Company repurchased 7,986 shares of its common stock at a cost of
$116 thousand during the three months ended September 28, 2024.
(3)There is no expiration date governing the period over which the Company can repurchase shares under its Board-approved share repurchase
program. Any repurchased shares are constructively retired and returned to an unissued status.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Plan and Non-r ule 10b5-1 Trading Arrangement Adoptions, Modifications and Terminations
One of the Company’s Board Members, Deborah L. Kilpatrick, adopted a trading arrangement for the sale of securities
of the Company’s common stock (a Rule 10b5-1 Trading Plan) that satisfied the affirmative defense conditions of
Securities Exchange Act Rule 10b5-1(c). Ms. Kilpatrick’s Rule 10b5-1 Trading Plan was adopted on August 2, 2024,
provides for the sale of up to 4,500 shares of common stock pursuant to the terms of the plan, and expires on December
31, 2025 or upon the earlier termination of the plan or sale of all shares subject to the plan.
None of the Company’s other directors or officers adopted, modified or terminated any contract, instruction or written
plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of
Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of SEC Regulation S-K, during
the quarter ended September 28, 2024.

29 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
ITEM 6. EXHIBITS

Exhibit Number |  | Description
10.1† |  | Transition and Advisory Agreement, dated October 24, 2024, between Sleep Number Corporation and Shelly R. Ibach (incorporated by reference to Exhibit 10.1 contained in Sleep Number’s Current Report on Form 8-K filed on October 30, 2024 (File No. 000-25121))
31.1* |  | Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2* |  | Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1* |  | Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
32.2* |  | Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
101.INS* |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH* |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL* |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE* |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104* |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*Filed Herein.
† Management contract or compensatory plan or arrangement.

30 | 3Q 2024 FORM 10-Q | SLEEP NUMBER CORPORATION

Index
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.

|  | SLEEP NUMBER CORPORATION
|  | (Registrant)
Dated: | November 5, 2024 | By: | /s/ Shelly R. Ibach
|  |  | Shelly R. Ibach
|  |  | Chief Executive Officer
|  |  | (principal executive officer)
|  | By: | /s/ Joel J. Laing
|  |  | Joel J. Laing
|  |  | Chief Accounting Officer
|  |  | (principal accounting officer)